Off the back of a string of positive announcements - DFU trial initial data, new CBO and first patient treated in aGVHD trial - Cynata CEO Dr Kilian Kelly sat down with Finance News Network to discuss The Company's milestones. Watch the interview below

In early March, the first patient was enrolled and treated in Cynata’s Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD).

Learn more here: https://bit.ly/4b0nkG7

Cynata has updated the market on the positive progress of its diabetic foot ulcers clinical trial.

Read Stockhead’s coverage here https://bit.ly/3P0mb8N 

Cynata is analysing wound surface areas in the first 16 patients of its Phase 1 trial for CYP-006TK, its off-the-shelf iPSC-derived MSC topical dressing for diabetic foot ulcers, with results expected by Q1 2024.

Understand more here

Following regulatory and ethics clearance to initiate a Phase 2 clinical trial for CYP-001 in patients with High-Risk acute Graft versus Host Disease at clinical sites in Turkey, Cynata plans to establish multiple clinical centers, commencing site initiation visits in the next 1-2 months. 

Read more here